BRAIN MONOAMINES, DRUGS AND CONDITIONED BEHAVIOR

拟议研究的第一个长期目标是 了解中枢神经系统神经递质的作用 系统在精神药物效应的作用中发挥作用 行为的维持。我们将重点关注多巴胺(DA)， 去甲肾上腺素(NE)和5-羟色胺(5-HT)及其 与操作者行为的关系。喂食、饮用和 运动也将被研究，因为它们很重要。 操作型行为的组成部分。的行为 神经递质将被药物和/或神经毒素改变。 将使用面向计算机的技术来测量行为。 我们将测量神经递质系统的变化 当通过给药修改操作行为时发生 抗抑郁药。这项研究的目的是阐明 中枢神经系统神经化学的变化导致 行为的改变，以及这些变化可能涉及 抑郁症的病理生理学。我们将衡量以下方面的变化 发射机周转作为行为的函数，可以解释 药物-行为-环境相互作用进一步 了解药物和环境的相对作用 行为的改变。 拟议研究的第二个目标是确定 单胺水平和单胺水平的长期变化 先前显示的退行性变的形态迹象 我们对甲基苯丙胺的神经毒性的研究，也是 由其他处方或滥用的厌食剂和 精神运动兴奋剂。苯非他明，扑热息痛， 扑热息痛、扑热息痛、扑热息痛和可卡因 做了神经毒性检查。我们将研究长期行为 与单胺类毒性相关的变化 甲基苯丙胺和致幻苯丙胺类似物， 包括3，4-亚甲二氧基苯丙胺(MDA)和3，4-亚甲二氧基苯丙胺 亚甲基二氧基甲基苯丙胺(MDMA)和可卡因。 第三个目标是详细研究通过什么机制 甲基苯丙胺和相关药物会产生神经毒性作用。 到目前为止，我们的结果表明，6-羟基多巴胺(6-羟基多巴胺) OHDA)和5，6-二羟色胺(5，6-DHT)在 大量服用冰毒后的脑部症状。我们建议 确认6-OHDA和5，6-DHT是在大脑中形成的 DA或5-羟色胺采用气相色谱和质谱学方法。 我们还将研究该反应的条件。 在体外、体外和体内发生。

The first long-range aim of the proposed research is to understand the role central nervous system neurotransmitter systems play in the action of psychotropic drug effects and in the maintenance of behavior. We will focus on dopamine (DA), norepinephrine (NE) and 5-hydroxytryptamine (5HT), and their relationship to operant behavior. Feeding, drinking and locomotion will also be studied since they are important components of operant behavior. The actions of neurotransmitters will be modified by drugs and/or neurotoxins. Behavior will be measured using computer-oriented techniques. We will measure changes in neuro-transmitter systems that occur when operant behavior is modified by administration of antidepressant drugs. The goal of this research is to elucidate changes in central nervous system neurochemistry which lead to changes in behavior and which may be involved in the pathophysiology of depression. We will measure the changes in transmitter turnover as a function of behavior that may account for drug-behavior-environment interactions to further understand the relative roles of drugs and the environment in modifications of behavior. The second aim of the proposed research is to determine whether the long-term alternations in monoamine levels and morphological signs of degeneration demonstrated previously in our research on the neurotoxicity of methamphetamine, is also produced by other prescribed or abused anorectics and psychomotor stimulants. Benzphetamine, phenmetrazine, phendimetrazine, phentermine, chlortermine and cocaine will be examined for neurotoxicity. We will study long-term behavioral changes associated with monoaminergic toxicity produced by methamphetamine and hallucinogenic amphetamine analogs, including 3,4-methylenedioxyamphetamine (MDA) and 3,4- methylenedioxymethamphetamine (MDMA), and cocaine. The third aim is to examine in detail the mechanism by which methamphetamine and related drugs produce neurotoxic effects. Our results to date have indicated that 6-hydroxydopamine (6- OHDA) and 5,6-dihydroxytryptamine (5,6-DHT) are formed in brain after a large dose of methamphetamine. We propose to confirm that 6-OHDA and 5,6-DHT are formed in the brain from DA or 5HT using gas chromatography and mass spectrometry. We shall also study the conditions under which this reaction occurs in vitro, ex vivo, and in vivo.